CCWM
CRSP icon

Cassaday & Co Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Cassaday & Co Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Sell
2,052
-208
-9% -$11K ﹤0.01% 453
2026
Q1 		$108K Buy
+2,260
New +$119K ﹤0.01% 446

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cassaday & Co Wealth Management's CRSP Position: Q2 2026 in Review

Cassaday & Co Wealth Management reduced its CRISPR Therapeutics (CRSP) stake by 9.2% in Q2 2026, selling an estimated $11K and leaving 2,052 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #453.

Cassaday & Co Wealth Management first reported a position in CRSP in Q1 2026 and has held it in 2 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Cassaday & Co Wealth Management held 2,052 shares of CRISPR Therapeutics worth $112K as of Q2 2026.
  • Cassaday & Co Wealth Management sold 208 CRISPR Therapeutics shares in Q2 2026, an estimated $11K.
  • CRISPR Therapeutics made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #453 holding.
  • Cassaday & Co Wealth Management first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.